Investment
Features
FeesSafety
Academy
More
Pluang+

FormFactor raises price target to $170 on strong Q2 earnings and growth outlook

Analyst Insights
15 Sep 2026
Seeking Alpha
View Source
Bullish
FormFactor raises price target to $170 on strong Q2 earnings and growth outlook

FormFactor beat Q2 2026 expectations with $258.2 million in revenue and $0.82 non-GAAP EPS, driven by strong multi-segment performance including HBM, GPU, and custom ASIC testing. The company qualified advanced MEMS technology at a leading foundry, boosting growth prospects. The analyst raised the 2028 non-GAAP EPS estimate from $3.34 to $4.25 and increased the price target from $134 to $170, applying a 40x forward P/E. Key risks include potential slowdowns in AI or HBM spending, execution challenges, and slower adoption of CPO technology.

FormFactor's recent earnings and price target update provide context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Sep 16, 2026 01:31 WIB: Of 150 priced US tech stocks, 58 rose and 91 fell. Notable movers include GoPro Inc (GPRO) at USD 1.29, down 4.44%, Expensify Inc (EXFY) at USD 2.38, up 4.39%, and Western Digital Corp (WDC) at USD 408.50, down 4.32%.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
1 hour ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
2 hours ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
3 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App